Sugi Predict

Sugi Predict / Compounds / SCHEMBL1712762

SCHEMBL1712762

SCHEMBL1712762

CCOC(=O)C(C)n1cc(B2OC(C)(C)C(C)(C)O2)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.46
▸ UCHL1 P09936 1/20 0.40
▸ DGAT1 O75907 1/20 0.34
▸ GSK3A P49840 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ LPL P06858 1/20 0.32
▸ LIPG Q9Y5X9 1/20 0.32
▸ MAPT P10636 2/20 0.32
▸ KDM4E B2RXH2 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ AAK1 Q2M2I8 1/20 0.31
▸ USP30 Q70CQ3 1/20 0.31
▸ L3MBTL1 Q9Y468 1/20 0.31
▸ ACHE P22303 3/20 0.31
▸ CYP1A2 P05177 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18530443 0.88 FFAR1 (0.44) FFAR1UCHL1DGAT1GSK3AGSK3B
SCHEMBL3663499 0.87 FFAR1 (0.45) FFAR1UCHL1DGAT1GSK3AGSK3B
SCHEMBL17801161 0.84 FFAR1 (0.48) FFAR1UCHL1DGAT1AAK1USP30
SCHEMBL13165395 0.84 FFAR1 (0.32) FFAR1UCHL1
SCHEMBL17352230 0.83 FFAR1 (0.48) FFAR1DGAT1GSK3AGSK3BLPL
SCHEMBL15514629 0.83 FFAR1 (0.48) FFAR1UCHL1DGAT1GSK3AGSK3B
SCHEMBL18614496 0.82 FFAR1 (0.42) FFAR1UCHL1DGAT1GSK3AGSK3B
SCHEMBL18895313 0.82 FFAR1 (0.47) FFAR1DGAT1USP30SMN1; SMN2
SCHEMBL11931387 0.82 FFAR1 (0.41) FFAR1UCHL1DGAT1LPLLIPG
SCHEMBL1485220 0.81 FFAR1 (0.51) FFAR1UCHL1DGAT1GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4596537-A1 NOVEL FLUORENE DERIVATIVE COMPOUND AND USE THEREOF JD Bioscience Inc. (KR) 2025-08-06 — — EP disclosed
US-20250163059-A1 HETEROCYCLIC KINASE INHIBITORS INCYTE CORPORATION 2025-05-22 — — US disclosed
EP-4304727-A1 EGFR INHIBITORS Blueprint Medicines Corporation (US) 2024-01-17 — — EP disclosed
US-20230019732-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2023-01-19 — — US disclosed
WO-2022192431-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2022-09-15 — — WO disclosed
EP-3042907-B1 DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) 2021-01-13 — — EP disclosed
EP-3042907-B1 DGAT1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF QUINGDAO HUANGHAI PHARMACEUTICAL CO LTD (CN) 2021-01-13 — — EP disclosed
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 INCYTE CORPORATION (US) 2020-10-27 — — US disclosed
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-01 — — US disclosed
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (JP) 2020-10-01 — — US disclosed
US-20130274240-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC (US) 2013-10-17 — — US disclosed
US-8343994-B2 Fluorene compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2013-01-01 — — US disclosed
US-8343994-B2 Fluorene compound and pharmaceutical use thereof JAPAN TOBACCO INC. (JP) 2013-01-01 — — US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 — — US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 — — US disclosed
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION 2012-06-28 — — US disclosed
WO-2012088266-A2 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 INCYTE CORPORATION (US) 2012-06-28 — — WO disclosed
EP-2345629-A1 FLUORENE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES Japan Tobacco, Inc. (JP) 2011-07-20 — — EP disclosed
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof JAPAN TOBACCO INC. (JP) 2010-09-23 — — US disclosed
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof JAPAN TOBACCO INC. (JP) 2010-09-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240634-A1 Fluorene Compound and Pharmaceutical Use Thereof FH, PCK2, PC FFAR1 554/4885UCHL1 2977/4885DGAT1 802/4885
US-20230019732-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 FFAR1 2680/4885UCHL1 2671/4885DGAT1 1666/4885
US-20130274240-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC FFAR1 554/4885UCHL1 2977/4885DGAT1 802/4885
US-20120165305-A1 SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3 FGFR3, FGFR4, FGFR2 FFAR1 3389/4885UCHL1 2972/4885DGAT1 4384/4885
US-10813930-B2 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 FGFR3, FGFR4, FGFR2 FFAR1 3389/4885UCHL1 2972/4885DGAT1 4384/4885
US-20200308109-A1 FLUORENE COMPOUND AND PHARMACEUTICAL USE THEREOF FH, PCK2, PC FFAR1 554/4885UCHL1 2977/4885DGAT1 802/4885
US-20250163059-A1 HETEROCYCLIC KINASE INHIBITORS JAK2, JAK1, JAK3 FFAR1 4670/4885UCHL1 4556/4885DGAT1 4414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.